Bristol-Myers’ nivolumab grabs its sixth breakthrough designation as new links to autoimmune diseases creep up
This morning the FDA handed out its 6th “breakthrough” drug designation for Bristol-Myers Squibb’s Opdivo (nivolumab), signaling once again the agency will continue to facilitate the checkpoint inhibitor’s rapid rollout in the oncology market.
Checkpoint inhibition has become BMS’ specialty, zipping ahead of Merck’s Keytruda (pembrolizumab) in the PD-1 arena as physicians glom on to this new treatment paradigm for orchestrating an immune system assault on cancer cells.
But as the drugs gain greater traction, there’s new evidence revving up the immune system has unintended consequences that could threaten a slice of the patient population.
Johns Hopkins has now stepped up with 13 case studies that link nivolumab and Yervoy (ipilimumab) to cases of inflammatory arthritis and other autoimmune conditions. And doctors expect to see that caseload grow as even more checkpoints are approved for wider use against cancer.
“We keep having referrals coming in from our oncologists as more patients are treated with these drugs,” says Clifton Bingham, M.D., associate professor of medicine at the Johns Hopkins University School of Medicine and director of the Johns Hopkins Arthritis Center. “In particular, as more patients are treated with combinations of multiple immunotherapies, we expect the rate to go up.”
None of that will prevent the use of these drugs in the cancer field, which has embraced checkpoint inhibition as a major advance in slowing or even halting cancer. The FDA’s latest Breakthrough Therapy Designation for nivolumab covers an advanced form of bladder cancer.